The placebo response of injectable GLP‐1 receptor agonists <i>vs</i>. oral DPP‐4 inhibitors and SGLT‐2 inhibitors: a systematic review and meta‐analysis

Wit, H.M. de; Groen, Maarten te; Rovers, Maroeska M.; Tack, Cees J.

doi:10.1111/bcp.12925

Cited by 21 publications

(10 citation statements)

References 103 publications

(250 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies demonstrated that GLP-1 analogues were more potent in lowering HbA 1c levels than DPP-4 inhibitors [ 14 , 15 ]. However, there was no difference in the improvement of HbA 1c between lixisenatide and vildagliptin in our study.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study

et al. 2018

View full text Add to dashboard Cite

IntroductionWe comprehensively evaluated the effects of combination therapy with insulin glargine and the incretin-based drugs lixisenatide or vildagliptin in Japanese patients with type 2 diabetes.MethodsIn this 12-week, randomized, open-label, parallel-group, multicenter study (GLP-ONE Kobe), the incretin-based drug sitagliptin was randomly switched to lixisenatide (20 μg/day, n = 18) or vildagliptin (100 mg/day, n = 20) in patients with inadequate glycemic control despite combination therapy with insulin glargine and sitagliptin. The dose of insulin glargine was titrated after the switch to maintain fasting blood glucose at approximately 110 mg/dL. The primary end points of the study were the change in glycosylated hemoglobin (HbA1c) level between before and 12 weeks after the treatment switch, the proportion of patients achieving an HbA1c level below 7.0%, and the postprandial increase in glucose concentration as assessed by self-monitoring of blood glucose.ResultsThe change in HbA1c level from baseline to 12 weeks did not differ significantly between the lixisenatide and vildagliptin groups (− 0.6 ± 0.7% and − 0.6 ± 1.2%, respectively, P = 0.920). Neither the proportion of patients achieving an HbA1c level below 7.0% nor the postprandial increase in glucose concentration was different between two groups. Body weight and serum low density lipoprotein (LDL) cholesterol level decreased significantly in the lixisenatide and vildagliptin groups, respectively. Both drugs were associated with mild gastrointestinal symptoms but not with severe hypoglycemia. Vildagliptin was associated with elevation of serum aspartate transaminase. Treatment satisfaction as assessed with the Diabetes Treatment Satisfaction Questionnaire did not differ significantly between the two groups.ConclusionThe combinations of basal insulin and either lixisenatide or vildagliptin have similar efficacies with regard to improvement of glycemic control.Trial RegistrationThis trial has been registered with UMIN (No. 000010769).Electronic supplementary materialThe online version of this article (10.1007/s13300-018-0505-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Studies in adults show reductions in HbA 1c , glycaemic variability, body weight and insulin doses, increased time in the target glycaemic range, and improvements in cardiovascular risk factors and mortality compared with placebo [95,96]. The weight loss and glucose lowering with SGLT2 inhibitors appears less than that observed with GLP-1 receptor agonists [98], but this class of drugs appears very effective for treatment of DKD in adults [99,100]. SGLT2 inhibitors are approved in Europe and Japan for adults with type 1 diabetes.…”

Section: Treatmentmentioning

confidence: 99%

The changing face of paediatric diabetes

Shah

Nadeau

2020

Diabetologia

View full text Add to dashboard Cite

The purpose of this review is to provide an update on the changing face of paediatric type 1 diabetes and type 2 diabetes. Paediatric diabetes is on the rise, with extensive research dedicated to understanding its pathophysiology, comorbidities and complications. As obesity continues to increase among all youth, differentiating between type 1 diabetes and type 2 diabetes has become increasingly difficult but remains important for optimising treatment, anticipating complications and predicting disease risk. Novel treatments are emerging, with the ultimate goal being to achieve glycaemic control, limit weight gain, improve quality of life and reduce comorbidities. In this review, we focus on updates regarding the epidemiology, clinical presentation, comorbidities and complications of paediatric type 1 diabetes and type 2 diabetes and conclude with current and emerging treatments.

show abstract

“…In Japan, DPP-4 inhibitors, including teneligliptin (TNL), are the most commonly prescribed antidiabetic drugs [12], and are suitable for both elderly and dialysis patients [13]. In addition, DPP-4 inhibitors are weight neutral [14][15][16]. It has been reported that, for patients responding inadequately to insulin, addition of a DPP-4 inhibitor to insulin therapy is more effective than a dose increase of insulin [10].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period

Kadowaki

Kondo

Sasaki

et al. 2017

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

The placebo response of injectable GLP‐1 receptor agonists vs. oral DPP‐4 inhibitors and SGLT‐2 inhibitors: a systematic review and meta‐analysis

Cited by 21 publications

References 103 publications

Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study

Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study

The changing face of paediatric diabetes

Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period

Contact Info

Product

Resources

About